Walker D J, Wakefield A E, Dohn M N, Miller R F, Baughman R P, Hossler P A, Bartlett M S, Smith J W, Kazanjian P, Meshnick S R
Department of Epidemiology, Division of Infectious Diseases, University of Michigan, Ann Arbor, MI 48109, USA.
J Infect Dis. 1998 Dec;178(6):1767-75. doi: 10.1086/314509.
Atovaquone (Mepron, 566c80) is an effective agent against Pneumocystis carinii, which probably acts by binding to cytochrome b and inhibiting electron transport. To assess the possibility that atovaquone resistance might be developing, the genes for the cytochrome b from P. carinii sp. f. carinii and P. carinii sp. f. hominis were partially sequenced. Eight of 10 patient isolates had cytochrome b genes with the same amino acid sequence. The P. carinii cytochrome b genes from 2 of 4 patients who had atovaquone prophylaxis failure contained mutations resulting in amino acid changes in one of the ubiquinone (coenzyme Q) binding sites (Qo). These mutations are homologous to mutations in other microorganisms that confer resistance to similar inhibitors. Variations in the sequence of the P. carinii cytochrome b gene suggest but do not prove the development of drug resistance.
阿托伐醌(Mepron,566c80)是一种抗卡氏肺孢子虫的有效药物,其作用可能是通过与细胞色素b结合并抑制电子传递来实现的。为评估可能正在出现阿托伐醌耐药性的情况,对卡氏肺孢子虫卡氏变种和卡氏肺孢子虫人变种的细胞色素b基因进行了部分测序。10个患者分离株中有8个的细胞色素b基因具有相同的氨基酸序列。4例接受阿托伐醌预防治疗失败的患者中,有2例的卡氏肺孢子虫细胞色素b基因发生了突变,导致其中一个泛醌(辅酶Q)结合位点(Qo)的氨基酸发生改变。这些突变与其他微生物中导致对类似抑制剂产生耐药性的突变同源。卡氏肺孢子虫细胞色素b基因序列的变化提示但未证实耐药性的产生。